JCM | Free Full-Text | Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar | Scientific Reports
Accelerated Infliximab Induction for Severe Lower Gastrointestinal Bleeding in a Young Patient with Crohn's Disease: A Case Report
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial - The Lancet Gastroenterology & Hepatology
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis | NEJM
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis | NEJM
Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease
Acute severe colitis: Accelerated induction Infliximab | Digestive Disease Dashboard
JCM | Free Full-Text | Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn's Disease and Ulcerative Colitis—A Prospective Polish Population Study
Frontiers | Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
Infliximab (Remicade).pdf - Marquette General Hospital
Remicade Dosage Guide - Drugs.com
JCM | Free Full-Text | An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
Clinical response after a single infliximab infusion versus three-dose... | Download Scientific Diagram
Induction and Maintenance Infliximab Therapy for the Treatment of Moderate-to-Severe Crohn's Disease in Children - ScienceDirect
JCM | Free Full-Text | A Practical Guide to Therapeutic Drug Monitoring of Biologic Medications for Inflammatory Bowel Disease
Protocol for administration of infliximab for acute severe ulcerative... | Download Scientific Diagram
Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis | Scientific Reports
Prognostic factors for long‐term infliximab treatment in Crohn's disease patients: a 20‐year single centre experience - Billiet - 2016 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis - Seungwon Yang, Siyoung Yang, Young Kwon Jo, Seungyeon Kim, Min Jung Chang, Junjeong Choi,
Infliximab retreatment results in remission in 35% of patients with Crohn's disease
Infliximab
Biologics Dose Escalation for the Treatment of Inflammatory Bowel Disease: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | Semantic Scholar
Colectomy free survival. Infliximab 5 versus 10 mg/kg induction. | Download Scientific Diagram
Accelerated Infliximab Infusion: Safety, Factors Predicting Adverse Events, Patients' Satisfaction and Cost Analysis. A Cohort
Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis - ScienceDirect
Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis - Clinical Gastroenterology and Hepatology
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease | NEJM
